title: Operating characteristics of a partial-block randomized crossover bioequivalence study for dutasteride, a drug with a long half-life: investigation through simulation and comparison with final results.
abstract: Studies to establish bioequivalence (BE) of a drug are important elements in support of drug applications. A typical BE study is conducted as a single dose, randomized, 2-period crossover design. For drugs with long half lives (≥ 48 hours) and evaluation of multiple BE objectives in 1 trial, this design may not be adequate. A parallel design may then be a more appropriate choice. However, parallel designs require increased sample size, which can become substantial. One option that is a compromise between the complete randomized block design and the parallel design is a partial-block crossover design. This approach came about during the development of a combination of dutasteride and tamsulosin. Previous experience with performing single-dose dutasteride studies suggested that 28 days of washout is needed between treatments because of its half-life of 7-9 days. Simulations were performed to assess the operating characteristics of this design using a previously developed PK model. Four scenarios were developed, and each scenario was simulated 500 times. The results showed that this design demonstrated acceptable consumer and producer risk. Partial-block crossover designs should be considered for studies when the half-life of the drug is long and there are more than 2 periods.
authors.affiliation: Department of Quantitative Sciences, GlaxoSmithKline, King of Prussia, PA 19406, USA. gengqian.2.cai@gsk.com
authors.forename: Gengqian
authors.initials: G
authors.lastname: Cai
authors.forename: Jake J
authors.initials: JJ
authors.lastname: Thiessen
authors.forename: Charlotte A
authors.initials: CA
authors.lastname: Baidoo
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Fossler
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000493:pharmacokinetics*; D019540:Area Under Curve; D001378:Azasteroids / Q000493:pharmacokinetics*; D003198:Computer Simulation; D018592:Cross-Over Studies; D000068538:Dutasteride; D006207:Half-Life; D006801:Humans; D008297:Male; D013810:Therapeutic Equivalency
chemical_list: D058891:5-alpha Reductase Inhibitors; D001378:Azasteroids; D000068538:Dutasteride